264 related articles for article (PubMed ID: 36199122)
1. Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer.
Liu S; Liu Z; Piao C; Zhang Z; Kong C; Yin L; Liu X
J Exp Clin Cancer Res; 2022 Oct; 41(1):293. PubMed ID: 36199122
[TBL] [Abstract][Full Text] [Related]
2. Histone H2A and H4 N-terminal tails are positioned by the MEP50 WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase.
Burgos ES; Wilczek C; Onikubo T; Bonanno JB; Jansong J; Reimer U; Shechter D
J Biol Chem; 2015 Apr; 290(15):9674-89. PubMed ID: 25713080
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic control via allosteric regulation of mammalian protein arginine methyltransferases.
Jain K; Jin CY; Clarke SG
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10101-10106. PubMed ID: 28874563
[TBL] [Abstract][Full Text] [Related]
4. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
[TBL] [Abstract][Full Text] [Related]
5. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
[TBL] [Abstract][Full Text] [Related]
6. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
[TBL] [Abstract][Full Text] [Related]
7. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance.
Zhu Y; Xia T; Chen DQ; Xiong X; Shi L; Zuo Y; Xiao H; Liu L
Drug Resist Updat; 2024 Jan; 72():101016. PubMed ID: 37980859
[TBL] [Abstract][Full Text] [Related]
8. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
[TBL] [Abstract][Full Text] [Related]
9. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program.
Huang M; Dong W; Xie R; Wu J; Su Q; Li W; Yao K; Chen Y; Zhou Q; Zhang Q; Li W; Cheng L; Peng S; Chen S; Huang J; Chen X; Lin T
Cancer Commun (Lond); 2022 May; 42(5):447-470. PubMed ID: 35434944
[TBL] [Abstract][Full Text] [Related]
10. OGG1 regulates the level of symmetric dimethylation of histone H4 arginine-3 by interacting with PRMT5.
Zhou X; Wang W; Du C; Yan F; Yang S; He K; Wang H; Zhao A
Mol Cell Probes; 2018 Apr; 38():19-24. PubMed ID: 29409673
[TBL] [Abstract][Full Text] [Related]
11. The macromolecular complexes of histones affect protein arginine methyltransferase activities.
Fulton MD; Cao M; Ho MC; Zhao X; Zheng YG
J Biol Chem; 2021 Oct; 297(4):101123. PubMed ID: 34492270
[TBL] [Abstract][Full Text] [Related]
12. Effects of substrate modifications on the arginine dimethylation activities of PRMT1 and PRMT5.
Fulton MD; Dang T; Brown T; Zheng YG
Epigenetics; 2022 Jan; 17(1):1-18. PubMed ID: 33380261
[TBL] [Abstract][Full Text] [Related]
13. Computational Study of Symmetric Methylation on Histone Arginine Catalyzed by Protein Arginine Methyltransferase PRMT5 through QM/MM MD and Free Energy Simulations.
Yue Y; Chu Y; Guo H
Molecules; 2015 May; 20(6):10032-46. PubMed ID: 26035101
[TBL] [Abstract][Full Text] [Related]
14. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Chen H; Lorton B; Gupta V; Shechter D
Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
[TBL] [Abstract][Full Text] [Related]
15. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
[TBL] [Abstract][Full Text] [Related]
16. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression.
Liu M; Yao B; Gui T; Guo C; Wu X; Li J; Ma L; Deng Y; Xu P; Wang Y; Yang D; Li Q; Zeng X; Li X; Hu R; Ge J; Yu Z; Chen Y; Chen B; Ju J; Zhao Q
Theranostics; 2020; 10(10):4437-4452. PubMed ID: 32292506
[TBL] [Abstract][Full Text] [Related]
17. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies.
Abumustafa W; Zamer BA; Khalil BA; Hamad M; Maghazachi AA; Muhammad JS
Biomed Pharmacother; 2022 Jan; 145():112368. PubMed ID: 34794114
[TBL] [Abstract][Full Text] [Related]
18. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.
Stopa N; Krebs JE; Shechter D
Cell Mol Life Sci; 2015 Jun; 72(11):2041-59. PubMed ID: 25662273
[TBL] [Abstract][Full Text] [Related]
19. Research Progress on Small-molecule Inhibitors of Protein Arginine Methyltransferase 5 (PRMT5) for Treating Cancer.
Guo C; Wu L; Zheng X; Zhao L; Hou X; Wang Z; Han C
Curr Top Med Chem; 2023; 23(21):2048-2074. PubMed ID: 37438905
[TBL] [Abstract][Full Text] [Related]
20. Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion.
Wang M; Fuhrmann J; Thompson PR
Biochemistry; 2014 Dec; 53(50):7884-92. PubMed ID: 25485739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
